BB Biotech Reports an MGNX Buy

JC Parets
October 26, 2022

The largest insider transaction on today’s list was reported in a Form 4 filing by the Swiss investment company BB Biotech AG.

The biotechnology-focused fund reported a purchase worth roughly $2.2 million in MacroGenics $MGNX.

In other Form 4 filings, both the Chief Risk Officer and a director of Texas Capital Bancshares $TCBI disclosed purchases of their own company's stock.

Here’s The Hot List, with data through October 25, 2022:

In another Form 4, director Kevin Stephens reported a purchase of 2,000 shares, equivalent to $247,000 of Crown Castle International $CCI stock.

In the options market, there was bullish flow in Microchip Technology $MCHP, Barrick Gold Corporation $GOLD, and Bed Bath & Beyond $BBBY.

Stay tuned. We'll be back Thursday with more insider action.

If you want these insider transactions e-mailed to you every morning, click here to sign up for The Hot Corner.

And please reach out with any questions. We love hearing from you!

All Star Charts Team

Filed Under: